At Nutriband and our subsidiaries, our core focus is to use innovative drug delivery systems and devices to improve patient outcomes, specifically targeting the Global Opioid epidemic. Fentanyl and other opioid based transdermal medications unfortunately play a role in a significant number of opioid deaths each year with no solution currently available. Working with our Clinical subsidiary 4P Therapeutics we have developed a technology called AVERSA which we believe with FDA approval will revolutionize the safety standard for these medications and save countless lives per year.
Research & Innovation
Through our Clinical Subsidiary 4P Therapeutics,Our Company has capabilities for developing pharmaceutical products from pre-clinical testing to clinical manufacturing and early stage clinical development (Phase I/II). A key company focus and area of expertise at 4P is in the development of transdermal products for currently injected compounds, including proteins, peptides, macromolecules and biologics. Transdermal delivery of commercially available drugs or biologics that are typically delivered via injection has the potential to improve safety, efficacy and therapeutic outcomes associated with these treatments.